Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

BACKGROUND: The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chron...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Headache Pain
Autores principales: Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Pierangeli, Giulia, Lovati, Carlo, Aguggia, Marco, d’Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Rao, Renata, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8091153/
https://ncbi.nlm.nih.gov/pubmed/33941080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-021-01247-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares